You are here

Article Text

Article menu
Download PDFPDF
Uterine Cancer
Cytochrome P450 1A1 Gene Polymorphisms and Endometrial Cancer Risk: A Meta-Analysis
  1. Theodoros N. Sergentanis, MD*,†,
  2. Konstantinos P. Economopoulos, MD*,†,
  3. Souzana Choussein, MD*,† and
  4. Nikos F. Vlahos, MD*,‡
  1. * School of Medicine, University of Athens;
  2. † Society of Junior Doctors, Athens, Greece; and
  3. ‡ Department of Gynecology and Obstetrics, School of Medicine, Johns Hopkins University, Baltimore, MD.
  1. Address correspondence and reprint requests to Theodoros N. Sergentanis, MD, Society of Junior Doctors, 5 Menalou St, Maroussi, Athens, 15123, Greece. E-mail: tsergentanis{at}sni.gr.

Abstract

Introduction: This meta-analysis aims to examine whether the genotype status of Msp1, Ile462Val, and Thr461Asn polymorphisms in cytochrome P450 1A1 (CYP1A1) is associated with endometrial cancer risk.

Methods: Eligible case-control studies were identified through search in MEDLINE (end of search: August 2010). Pooled odds ratios (ORs) were appropriately derived from fixed-effects or random-effects models.

Results: Concerning MspI polymorphism, 8 studies were eligible (1456 cases and 2371 controls); 9 studies were eligible (1889 cases and 3662 controls) for Ile462Val and 6 studies were eligible (1272 cases and 2122 controls) for Thr461Asn. MspI polymorphism was not associated with endometrial cancer risk (for heterozygous TC vs TT carriers: OR = 0.83, 95% confidence interval [CI], 0.59-1.15, random effects; for homozygous CC vs TT carriers: OR = 1.00, 95% CI, 0.55-1.82, fixed effects). Similarly, Ile462Val polymorphism was not associated with endometrial cancer risk (for heterozygous Ile/Val vs Ile/Ile carriers: OR = 1.27, 95% CI, 0.78-2.06, random effects; for homozygous Val/Val vs Ile/Ile carriers: OR = 1.16, 95% CI, 0.48-2.81, fixed effects). Accordingly, Thr461Asn status was not significantly associated with endometrial cancer risk. The same results were reproduced in Caucasians.

Conclusions: The 3 examined CYP1A1 genotype polymorphisms do not seem to confer any additional risk for endometrial cancer in Caucasians. Accumulation of further data seems mandatory for future race-specific analyses.

  • Cytochrome P450 1A1
  • Endometrial cancer
  • MspI polymorphism
  • Ile462Val polymorphism
  • Thr461Asn polymorphism

https://doi.org/10.1097/IGC.0b013e31820575c0

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.